Development of imiquimod-loaded mucoadhesive films for oral dysplasia.

Oral squamous dysplasia, which can usually be readily visualized as leukoplakia during an oral examination and confirmed by histology, is often considered a premalignant condition. Current treatments, however, focus on the final stages of disease, and treatments such as surgery can lead to postoperative disabilities. Hence, this study was designed to develop a noninvasive, mucoadhesive drug delivery system loaded with an immune response modifier, imiquimod, as a treatment for precancerous dysplastic lesions. Blends of polyvinylpyrrolidone and carboxymethylcellulose were used to prepare mucoadhesive films that were backed with poly(ethylene-co-vinyl acetate). Because of the hydrophobic nature of imiquimod, four loading methods (sonication, linoleic acid, 2-hydroxypropyl-β-cyclodextrin, and acetate buffer) were compared. The formation of imiquimod-cyclodextrin complexes and their solubility was studied by differential scanning calorimetry and phase solubility studies. All films achieved sustained release of drug for 3 h except those prepared by linoleic acid. The high solubility of imiquimod in acetate buffer facilitated high loading capacity and greater release (68%) of drug than did the other formulations (approximately 40%). In summary, a noninvasive and local approach with the potential to treat precancerous lesions may be achieved by this described mucoadhesive drug delivery system.

[1]  Zhonggui He,et al.  Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin. , 2006, International journal of pharmaceutics.

[2]  S. Schwendeman,et al.  Development and In Vitro-In Vivo Evaluation of Fenretinide-Loaded Oral Mucoadhesive Patches for Site-Specific Chemoprevention of Oral Cancer , 2011, Pharmaceutical Research.

[3]  A. Mahmoud,et al.  Formulation of Indomethacin Eye Drops via Complexation with Cyclodextrins , 2011, Current eye research.

[4]  S. Weintraub,et al.  Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. , 2010, The Journal of clinical investigation.

[5]  R. Gaud,et al.  FORMULATION OF A WATER SOLUBLE MUCOADHESIVE FILM OF LYCOPENE FOR TREATMENT OF LEUKOPLAKIA , 2010 .

[6]  K. Cho,et al.  A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision. , 2009, Annals of dermatology.

[7]  David S Jones,et al.  Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity. , 2009, International journal of pharmaceutics.

[8]  Jashin J. Wu,et al.  Off-label indications for imiquimod. , 2009, Dermatology online journal.

[9]  S. Mutalik,et al.  Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study , 2009, Pharmaceutical development and technology.

[10]  B. Thiers Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod , 2009 .

[11]  V. Kadam,et al.  Mucoadhesive Bilayered Patches for Administration of Sumatriptan Succinate , 2008, AAPS PharmSciTech.

[12]  Y. Pore,et al.  Effect of β-cyclodextrin complexation on physicochemical properties of zaleplon , 2008 .

[13]  V. Khutoryanskiy,et al.  Mucoadhesive and elastic films based on blends of chitosan and hydroxyethylcellulose. , 2008, Macromolecular bioscience.

[14]  T. Bieber,et al.  Successful treatment of extensive human papillomavirus‐associated oral leucoplakia with imiquimod , 2007, The British journal of dermatology.

[15]  S. Baboota,et al.  Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. Preparation and properties of rofecoxib hydroxypropyl β-cyclodextrin inclusion complex: A technical note , 2005, AAPS PharmSciTech.

[16]  R. Kaufmann,et al.  Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa. , 2006, The Lancet. Oncology.

[17]  P. McCarron,et al.  Design and physicochemical characterisation of a bioadhesive patch for dose-controlled topical delivery of imiquimod. , 2006, International journal of pharmaceutics.

[18]  Jianqing Gao,et al.  Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin. , 2006, International journal of pharmaceutics.

[19]  A. Chakrabarty,et al.  Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. , 2005, Journal of the American Academy of Dermatology.

[20]  Carlo Rossi,et al.  Development of mucoadhesive patches for buccal administration of ibuprofen. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[21]  L. Fenart,et al.  Behavior of α-, β-, and γ-Cyclodextrins and Their Derivatives on an in Vitro Model of Blood-Brain Barrier , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  L. Golitz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.

[23]  Roger A. Rajewski,et al.  Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.

[24]  Ping I. Lee,et al.  A New Bioerodible Polymer Insert for the Controlled Release of Metronidazole , 1994, Pharmaceutical Research.

[25]  A. Rebora,et al.  Occlusive medication with imiquimod in Bowen's disease. , 2004, Acta dermato-venereologica.

[26]  W. Sterry,et al.  Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low‐frequency dosing with and without occlusion , 2002, The British journal of dermatology.

[27]  C. Twelves,et al.  Oral cancer treatment: developments in chemotherapy and beyond , 2002, British Journal of Cancer.

[28]  R. Sinisterra,et al.  An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-beta-cyclodextrin and benzaldehyde semicarbazone. , 2002, Biochemical and biophysical research communications.

[29]  T. Day,et al.  Oral Cancer and Precancerous Lesions , 2002, CA: a cancer journal for clinicians.

[30]  K. Chowdary,et al.  Nimesulide and β-Cyclodextrin Inclusion Complexes: Physicochemical Characterization and Dissolution Rate Studies , 2000, Drug development and industrial pharmacy.

[31]  C. Wong,et al.  An in-vitro method for buccal adhesion studies: importance of instrument variables. , 1999, International journal of pharmaceutics.

[32]  M. Jozwiakowski,et al.  Development of a topically active imiquimod formulation. , 1999, Pharmaceutical development and technology.

[33]  J. Szejtli Introduction and General Overview of Cyclodextrin Chemistry , 1998 .

[34]  J. Szejtli Introduction and General Overview of Cyclodextrin Chemistry. , 1998, Chemical reviews.

[35]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[36]  Javed Ali,et al.  Mucoadhesive Drug Delivery Systems , 1997 .

[37]  W. Galey,et al.  The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. , 1976, The Journal of investigative dermatology.

[38]  T. Higuchi,et al.  Phase solubility techniques , 1965 .